<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593463</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA010017-01</org_study_id>
    <secondary_id>57184</secondary_id>
    <secondary_id>R01DA010017</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00593463</nct_id>
  </id_info>
  <brief_title>Drug Discrimination in Methadone-Maintained Humans Study 1</brief_title>
  <acronym>OMDD1</acronym>
  <official_title>Drug Discrimination in Methadone-Maintained Humans Study 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves giving psychoactive drugs intramuscularly (injected into the muscle of
      the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the
      difference between one drug and another, as well as measuring the effects of the drugs on
      mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each
      subject will receive 2-4 of the listed interventions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Discrimination Measure</measure>
    <time_frame>Every session</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported effects</measure>
    <time_frame>Every Session</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Every session</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 2-4 of the interventions listed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycloserine</intervention_name>
    <description>Cycloserine: 500, 675, 750 mg oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Calan</other_name>
    <other_name>Veralan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>Diltiazem: 30, 60, 120 mg oral capsule may possibly be</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cardizem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin: 100, 200, 400 mg oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isradipine</intervention_name>
    <description>Isradipine: 5, 10 mg oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>DynaCirc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Narca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Nifedipine: 5, 10, 20 mg oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Adalat</other_name>
    <other_name>Procardia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline: I.M. injection may possibly be given</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Verapamil: 30, 60, 120 mg oral capsule may possibly be given</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Veralan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be between the ages of 18-65.

          2. Participation in the UAMS Substance Abuse Treatment Clinic Methadone Maintenance
             Program or the CATAR Clinic Little Rock with maintenance on a stable dose of methadone
             (+ or - 10 mg) for at least 1 month prior to study entry.

          3. Subjects would have to be in &quot;good standing&quot; in the methadone maintenance program in
             order to participate; i.e., compliance with scheduled medication and group therapy
             session hours. This would be defined as &lt; 3 missed methadone medications and missed &lt;
             3 group or &lt;3 individual therapy sessions in the two months prior to study
             participation

          4. Subjects must submit a urine sample negative for illicit drugs prior to study entry.

          5. Subjects must be able to read and understand English.

        Exclusion Criteria:

        Exclusion criteria

          1. Ill health (major cardiovascular, renal, endocrine, hepatic disorder, to be determined
             by history provided by the prospective subject or laboratory evaluation as outlined
             below).

          2. Current diagnosis of other drug or alcohol physical dependence (other than tobacco).

          3. History of major psychiatric disorder (psychosis, schizophrenia, bipolar, depression)

          4. Pregnancy, plans to become pregnant or inadequate birth control.

          5. Present or recent use of over-the-counter psychoactive drug, prescription psychoactive
             drug or drug that would have major interaction with drugs to be tested.

          6. History of severe reaction to Narcan challenge, which may have been given as part of
             admission into the Methadone Maintenance Program or to reverse overdose.

          7. Liver function tests greater than 3 times normal, BUN and Creatinine outside normal
             range, or thyroid function tests outside normal range.

          8. EKG abnormalities including but not limited to: bradycardia (&lt;60 bpm); prolonged with
             QTc interval (&gt;420 msec); Wolff-Parkinson White syndrome; wide complex tachycardia;
             2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle
             branch block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Oliveto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>March 10, 2011</last_update_submitted>
  <last_update_submitted_qc>March 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alison Oliveto, Ph.D./Principal Investigator</name_title>
    <organization>University of Arkansas for Medical Sciences</organization>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>methadone</keyword>
  <keyword>opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Isradipine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

